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ABSTRACT: Recently, the tryptophan-containing noncatio-
nizable opioid peptides emerged with atypical structure and
unexpected in vivo activity. Herein, we describe analogs of the
naturally occurring mixed κ/μ-ligand c[Phe-D-Pro-Phe-Trp] 1
(CJ-15,208). Receptor affinity, selectivity, and agonism/
antagonism varied upon enlarging macrocycle size, giving the
μ-agonist 9 or the δ-antagonist 10 characterized by low
nanomolar affinity. In particular, the μ-agonist c[β-Ala-D-Pro-
Phe-Trp] 9 was shown to elicit potent antinociception in a
mouse model of visceral pain upon systemic administration.
■ INTRODUCTION
The cyclotetrapeptide (CTP) c[Phe-D-Pro-Phe-Trp] 1 (CJ-
15,208),1 isolated from the fermentation broth of the fungus
Ctenomyces serratus ATCC15502, came to the spotlight for its
unusual opioid activity. In vitro, 1 was a modestly selective
KOR ligand, with a IC50 of 47 nM, while affinities for MOR and
DOR were 260 and 2600 nM, respectively, and antagonist
activity against the KOR agonist asimadoline in the rabbit vas
deferens smooth muscle assay was EC50 = 1300 nM.
1 The
antagonist behavior was confirmed by the [32S]GTPγS
functional test.2 Ala-scan highlighted the importance of the
residues Phe3 and Trp4; indeed, c[Ala-D-Pro-Phe-Trp] 2
(Figure 1) showed low nanomolar affinity for KOR and
MOR, while the other Ala derivatives suffered a substantial loss
in binding affinity.3 The reversal of the configuration at Trp
gave 3 (Figure 1), a dual KOR/MOR antagonist in the
[32S]GTPγS test, IC50 = 140 nM.
2 Also for 3, Ala-scan was not
tolerated at positions 3 and 4, since c[Ala-D-Pro-Phe-D-Trp] 4
was the only compound equipotent to 3 (Figure 1).2
All derivatives of 1 maintained the same mixed KOR > MOR
affinity profile, albeit with different Ki values, and did not
exhibit any agonist activity in vitro. In vivo, the Ala derivatives
showed somewhat contrasting activities compared to the parent
compounds. As expected, epimer 3 behaved as a KOR
antagonist also in vivo and prevented the stress-induced
reinstatement of extinguished cocaine-seeking behavior.4 In
contrast, the natural isomer 1 exhibited robust antinociceptive
activity in the warm-water tail withdrawal test following icv
administration.4 Intriguingly, also the Ala analog 4 produced
potent OR-mediated antinociception in vivo.5 Finally, 1 and 3
were found to be active after oral administration and appeared
to penetrate the CNS.6,7
The structures of CTP 1 and all its derivatives appear clearly
correlated to that of the cyclopentapeptide (CPP) c[Phe-Gly-
Tyr-D-Pro-D-Trp].8 Discovered independently from 1, the CPP
was designed as a cyclic analogue of the endogenous MOR
agonist H-Tyr-Pro-Trp-PheNH2 endomorphin-1 (EM1).
9
These Trp-containing macrocycles are clearly distinct from
the classic opioid peptide agonists, as they lack the protonable
amino group of Tyr1, generally regarded as the fundamental
“message” pharmacophore.10,11 The CPP was a selective MOR
ligand with a 10−8 M affinity, acting as a partial agonist at MOR
in the cAMP functional assay.8 After systemic administration, it
produced antinociception in a mouse model of visceral pain,12
while the parent EM1 was completely ineffective.13,14
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Figure 1. Structures of 1 and of the analogue 2 identified by Ala-scan;
OR affinities (Ki, nM) of 1, 2, and their [D-Trp
4] stereoisomers 3, 4.
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Subsequent modifications gave c[Phe-Gly-Tyr-Gly-D-Trp] and
c[Phe-D-isoAsp-β-Ala-D-Trp], which showed 10-fold improved
MOR affinity while maintaining the agonist profile.15 Experi-
ments aimed at determining the minimal bioactive sequence
identified the MOR-selective agonist tripeptide Ac-D-Trp-Phe-
GlyNH2.
16 The introduction of different substituents at the
indole of D-Trp was shown to influence BBB permeability,
giving measurable central antinociception mediated by MOR in
the mouse warm-water tail withdrawal assay after ip
administration.17
Despite the close structural similarities, the two families of
opioid peptides showed distinct receptor selectivity and in vivo
activity. This led us to presume a correlation between
bioactivity and 3D displays of the shared bunch of
pharmacophores, which depend in turn on stereochemistry,
ring size, and secondary structures. As a consequence, we
designed selected analogues of the leads 1 and 2 (Figure 2),
and we analyzed receptor affinity and selectivity, aiming at
obtaining molecular picklocks capable of specifically interacting
with MOR, DOR, or KOR.
■ RESULTS AND DISCUSSION
The analogues of 1 utilized in this study are shown in Figure 2.
Previous SAR investigations2,3 pointed at Trp as the
fundamental residue of the parent peptide. To better analyze
the role of the indole ring of Trp, we designed the peptides
c[Phe-D-Pro-Phe-(1-MeTrp)] 5 and c[Phe-D-Pro-Phe-D-(1-
MeTrp)] 6, analogues of 1 and 3, respectively, in which the
nitrogen of indole was methylated. Peptides 7 and 8 were
designed as analogues of 2 characterized by the reversal of
stereochemistry at residue 1 or 3. The introduction of β-Ala
and GABA (γ-aminobutyric acid acid) in place of Ala1 gave the
analogues 9 and 10, respectively, characterized by increasing
macrocycle size.
The cyclopeptides of general structure c[Xaa1-D-Pro2-L-Phe/
D-Phe3-Trp4] were obtained from the linear sequences H-Trp-
Xaa-D-Pro-L/D-Phe-OH. Each enantiomer of 1-MeTrp was
prepared as described elsewhere, by the asymmetric Friedel−
Crafts alkylation of 1-methylindole with a dehydroalanine
derivative equipped with a chiral auxiliary, promoted by SnCl4
and phenol.18 The linear peptides were prepared in turn by
MW-assisted solid-phase synthesis on a Wang resin, using
Fmoc-protected amino acids and HBTU/HOBt/DIPEA as
activating agents. Fmoc deprotection was performed with
piperidine in DMF under MW irradiation. To cleave the
peptides, the resin was treated with TFA in the presence of
scavengers. Peptide purities were determined to be 69−84% by
reversed-phase (RP) HPLC, and their identity was checked by
electrospray ionization mass spectrometry (ESI MS) (Table
S1).
Cyclization was performed without prior purifications by
slow addition of the crude linear peptides to a solution of
HATU/DIPEA in DMF at rt, using a temporized syringe to
achieve pseudo-high-dilution conditions.3,19 The cyclic peptides
were isolated by semipreparative RP HPLC, and purities were
determined to be 95−98% by RP HPLC (Table S1) and
elemental analysis. The identity of the compounds was
confirmed by ESI MS, 1H NMR, 2D gCOSY, and 13C NMR
analyses. The CTPs 7 and 8 were recovered in lower yields as
compared to 5 and 6, suggesting the optimality of the
stereochemistry pattern of the native compound. In particular,
the reaction of H-Trp-Ala-D-Pro-D-Phe-OH under the con-
ditions described above gave the desired 8 only in traces. The
yield was increased to a moderate 55% starting from the
alternative precursor H-Ala-D-Pro-D-Phe-Trp-OH in the
presence of 10 equiv of NaHCO3 to assist in the macro-
cyclization of the peptide and heating the reaction mixture by
MW irradiation (45 °C) for 10 min before quenching. The 13-
and 14-membered analogues 9 and 10 were obtained in almost
quantitative yields (Table S1). This was not unexpected; CTPs
Figure 2. Structures of the CTPs 5−10 and analogues of 1 and 2
utilized in this study.
Table 1. In Vitro OR Affinities of the CTPs and Reference Compounds for hORsa
Ki (nM)
a
compd sequence MOR DOR KOR
DAMGO H-Tyr-D-Ala-Gly-NMePhe-Glyol 1.5 ± 0.1
DPDPE H-Tyr-c[D-Pen-Gly-Phe-D-Pen]-OH 3.30 ± 0.05
U50,488 nonpeptide 2.90 ± 0.04
1 c[Phe-D-Pro-Phe-Trp] 127 ± 13 >105 32 ± 4
5 c[Phe-D-Pro-Phe-(1-MeTrp)] b >105 >105
6 c[Phe-D-Pro-Phe-D-(1-MeTrp)] >105 >105 >105
7 c[D-Ala-D-Pro-Phe-Trp] >105 >105 >105
8 c[Ala-D-Pro-D-Phe-Trp] >105 >105 >105
9 c[β-Ala-D-Pro-Phe-Trp] 4.1 ± 1.2 >105 >105
10 c[GABA-D-Pro-Phe-Trp] b 3.08 ± 005 >105
aMean of 4−6 determinations ± SE. bRadioligand displacement <50% up to 10−2 M.
Journal of Medicinal Chemistry Brief Article
DOI: 10.1021/acs.jmedchem.6b00420
J. Med. Chem. 2016, 59, 9255−9261
9256
composed of all α-amino acids may be difficult to synthesize,
due to the highly constrained conformation required for
cyclization.20 In contrast, the introduction of β- or γ-residues
renders the structures easier to synthesize and conformationally
more stable.20−22
Binding Affinity to Human ORs. To evaluate compounds’
affinity toward the ORs, displacement binding assays were
performed in HEK-293 cells expressing the cloned human (h)
MOR, DOR, or KOR, using [3H]DAMGO, [3H]-
diprenorphine, or [3H]U69,593 as specific radioligands,
respectively. The reference compounds DAMGO, DPDPE,
and U50,48823 (Figure S3), showed Ki values in the nM range
and high selectivity to the respective receptors (Table 1), as
expected (Supporting Information). The parent 1 displayed
KOR > MOR affinity consistent with that previously
reported.1−3 As it regards the analogues, they showed a wide
range of different affinity and selectivity (Table 1).
The CTPs 5 and 6, which include L-(1-MeTrp) or D-(1-
MeTrp) in their sequence, showed null or negligible OR
affinity. These findings highlighted the importance of indole
NH in peptide/receptor interaction.15,24 Peptides 7 and 8 did
not show any significant receptor affinity, confirming the
relevance of the relative 3D display of the pharmacophores,
since 7 and 8 share the same sequence as the potent KOR/
MOR ligand 2,3 with inverted configuration at residue 1 or 3. In
contrast, the introduction of β-Ala in place of Ala1 yielded the
13-membered CTP 9, a highly selective MOR ligand (Ki = 4.1
nM, Table 1). Surprisingly, a further enlargement of ring size by
introducing GABA at position 1 determined a different receptor
selectivity: the 14-membered 10 showed very little affinity to
MOR and gained a noteworthy DOR affinity (Ki = 3.08 nM,
Table 1).
Conformational Analysis. To shed light on the different
receptor selectivity of the CTPs, the backbone conformations
of the KOR > MOR ligand 1, the MOR-selective 9, and the
DOR ≫ MOR 10 were investigated in solution by NMR
analysis and molecular dynamics simulations (MD). 1H NMR
spectroscopy was performed in 8:2 mixtures of [D6]dimethyl
sulfoxide (DMSO) and H2O, recommended as excellent
representative of biological fluids for the analysis of opioid
peptides.25,26 For all compounds but 9, the spectra showed a
single set of resonances, suggestive of conformational
homogeneity or a rapid equilibrium between conformers. In
contrast, 9 showed two distinct sets of sharp resonances at
about 2:1 ratio (Supporting Information). This CTP appeared
as a single peak in RP and direct HPLC under different
conditions, likely excluding the possibility to separate the two
conformers (Supporting Information).
Variable-temperature (VT) NMR experiments were used to
detect if amide protons were involved in intramolecular
hydrogen-bonding or were solvent-exposed. The Δδ/Δt
parameters of 1 (Table 2) revealed that the amide protons
Phe3NH and Trp4NH were nearly completely insensitive to
increasing temperature (for both, Δδ/Δt = −0.8 ppb/K),
suggesting the plausible occurrence of conformations having
Phe3NH and Trp4NH involved in very strong hydrogen bonds.
In contrast, the analysis of the major conformer 9A indicated a
strong hydrogen bond on TrpNH (−1.0 ppb/K). The minor
conformer 9B and 10 did not show evidence of strong
hydrogen bonding. However, the comparison of the Δδ/Δt
parameters was suggestive of significant populations of
conformers stabilized by a hydrogen bond on β-AlaNH for
9B (−2.0 ppb/K) and GABANH for 10 (−2.4 ppb/K).
Subsequently, the model compounds were analyzed by 2D-
ROESY in DMSO-d6/H2O (8:2). Cross-peaks intensities were
ranked to infer plausible interproton distances (Supporting
Information). Structures consistent with the spectroscopic
analyses were obtained by restrained MD simulations,27 using
the ROESY-derived distances as constraints, and minimized
with AMBER28 force field. Simulations were conducted in a box
of explicit water molecules starting from a set of random
structures.27 The structures were subjected to high-temperature
restrained MD with a scaled force field, followed by a
simulation with full restraints. The system was gradually
cooled, and the structures were minimized28 and clustered by
the rmsd analysis of the backbone atoms. The conformers 9A
and 9B were analyzed separately. For all compounds, this
procedure gave one major cluster comprising the large majority
of the structures. The representative structures with the lowest
energy and the least number of restraint violations were
selected and analyzed (Figure 3). To analyze the dynamic
behavior of the peptides, the structures were subjected to
unrestrained MD simulations in a box of water at rt.
In the structure 1A, D-Pro2 was embedded into a γ-turn
stabilized by the explicit hydrogen bond Phe3NH-Phe1CO.
This structure (γ@D-Pro2) accounted for the hydrogen bond
on Phe3NH predicted by VT-NMR. On the other hand, the
analysis of the trajectories of the unrestrained MD simulations
revealed the alternative structure 1B (Figure 3), characterized
by an inverse type II β-turn centered on D-Pro2-Phe3 (βII′@D-
Pro2-Phe3), stabilized by the hydrogen bond Trp4NH-PheC
O, in agreement with the temperature coefficient of TrpNH.
Table 2. Δδ/Δt Values (ppb/K) for the Amide Protons of 1,
9 (Conformers A and B), and 10 in 8:2 DMSO-d6/H2O
compd sequence NH1 NH3 NH4
1 c[Phe1-D-Pro2-Phe3-Trp4] −1,5 −0,8 −0,8
9A c[β-Ala1-D-Pro2-Phe3-Trp4] −3.3 −5.0 −1.0
9B −2.0 −4.2 −4.1
10 c[GABA1-D-Pro2-Phe3-Trp4] −2.4 −5.9 −6.2
Figure 3. Representative conformers of the CTPs 1, 9, and 10. For
clarity, only α and NH hydrogens are shown.
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The conformers A and B of 9 differed in the opposite
orientation of the amide bond between Phe3 and Trp4.
Therefore, 9A adopted an inverse type II β-turn on D-Pro2-
Phe3 (βII′@D-Pro2-Phe) with the hydrogen bond Trp4NH-
GABA1CO, while 9B was characterized by a regular type II
β-turn on Phe3-Trp4 (βII@Phe3-Trp4) and the hydrogen bond
β-Ala1NH-D-Pro2CO, confirming the results of VT NMR
(Figure 3). Both conformers were found highly stable during
the unrestrained MD simulations, and interconversion was not
observed, possibly explaining the occurrence of two sets of
distinct NMR resonances. Finally, the structure of 10 did not
show any hydrogen bond. Nevertheless, the analysis of the MD
trajectories revealed an equilibrium between the βII@Phe3-Trp4
conformer A (Figure 3), stabilized by the hydrogen bond
GABA1NH-D-Pro2CO, and the γ@Trp4 conformer B, the
latter with the hydrogen bond Phe3CO-GABA1NH,
consistent with the VT-NMR data.
The comparison of the 3D structures in Figure 3 suggested
that the different receptor selectivity of 1, 9, and 10 might
depend on the alternative backbone secondary structures.
Despite of the occurrence of the two conformers βII′@D-Pro2-
Phe3 A and βII@Phe3-Trp4 B, 9 was a potent and selective
MOR ligand. Docking studies aimed at investigating the poses
of the two conformers within the crystal structure of MOR in
the active state will be performed in due course. At present, it
could be supposed that the predominant KOR affinity of 1
might be correlated to the γ@D-Pro2 conformer A, while the
second conformer βII′@D-Pro2-Phe3 B would be responsible
for the significant MOR affinity. As for the DOR > MOR ligand
10, the coexistence of the two conformers γ@Trp4 B and βII@
Phe3-Trp4 A would explain the preferential DOR affinity of 10
and its residual ability to bind to MOR.
Pharmacological Characterization of 9 and 10. The
functional activity of the potent and selective MOR ligand 9
and of the DOR ≫ MOR ligand 10, was investigated by the
cAMP test in whole HEK-293 cells stably expressing hMOR
(HEK/MOR) or hDOR (HEK/DOR). The reference com-
pounds morphine and DAMGO for HEK/MOR, and DPDPE
for HEK/DOR, significantly inhibited forskolin-induced cAMP
accumulation, with IC50 values of 4.3, 19, and 1.6 nM and Emax
(the maximal obtainable effect) of 77%, 95%, and 89%,
respectively (Table 3), as expected (Supporting Information).
The MOR-specific 9 inhibited forskolin-induced cAMP
accumulation, with IC50 = 6.1 nM and Emax = 90%, suggestive
of a full agonist behavior (Table 3). The DOR ≫ MOR ligand
10 inhibited forskolin-induced cAMP accumulation in HEK/
MOR, albeit with a worse IC50 (183 nM; Table 3).
Interestingly, 10 did not alter forskolin-induced cAMP
accumulation in HEK/DOR but significantly antagonized in a
concentration-related manner the inhibition of forskolin-
induced cAMP accumulation by 10 μM DPDPE (Table 3),
with IC50 = 7.4 nM.
Considering that 1 is well-known to have KOR antagonist
properties and its analogs have been reported with antagonist
effects at the MOR and DOR as well, the ability of 9 to
counteract DAMGO-, DPDPE-, or U50,488-mediated inhib-
ition of forskolin-induced cAMP accumulation was investigated.
Nevertheless, 9 did not display any antagonist activity (data not
shown); similarly, 10 did not alter DAMGO activity at MOR
and U50,488 activities at KOR (data not shown).
Albeit accompanied by severe side effects, MOR agonists are
still the most potent and widely used analgesics. For this
reason, on prosecuting a program dedicated to the discovery of
new opioid peptides showing analgesic activity in
vivo,12,13,17,29,30 we turned our attention to the potent and
selective MOR agonist 9. Preliminarily, incubation in mouse
serum for 3 h (Supporting Information)12 allowed confirming
the enzymatic stability of 9, as generally observed for bioactive
cyclopeptides,31,32 including 1 and 3.6,7 Subsequently, the
peripheral preempitive antinociceptive effect elicited by 9 was
determined in a mouse model of visceral pain, as previously
reported.12 Mice were injected with 0.6% AcOH into the
peritoneal cavity, thus triggering abdominal stretching
combined with an exaggerated extension of the hindlimbs.
Animals treated with vehicle 5 min prior to AcOH challenge
displayed an average of 35.0 ± 5.5 abdominal writhes during
the 10 min observation after injection. On the contrary, when
given 5 min before AcOH challenge, 9 (0.5−10 mg/kg ip)
produced a dose-related decrease in the number of abdominal
writhes evoked by AcOH (Figure 4), ED50 = 0.64 ± 0.06 mg/
kg. Interestingly, 9-mediated antinociceptive effect was counter-
acted by pretreating the animals with the opioid antagonist
NLX (30 mg/kg, ip) but not by the DOR selective antagonist
NTD (10 mg/kg, ip) or by the KOR selective antagonist
norBNI (10 mg/kg, ip), thus confirming that the observed
effect is MOR-dependent and does not involve any other
opioid receptor such as peripherally expressed KOR.
Antinociception elicited by 9 would not affect behavioral
Table 3. Inhibitory Effects of 9 and 10 on Forskolin-Induced
cAMP Formation in HEK/MOR and of 10 (Alone or





morphine (HEK/MOR) 4.3 ± 0.4 77 ± 4
DAMGO (HEK/MOR) 19.3 ± 1.1 95 ± 4
DPDPE (HEK/DOR) 1.6 ± 0.3 89 ± 3
9 (HEK/MOR) 6.1 ± 0.3 90 ± 5
10 (HEK/MOR) 183 ± 47 82 ± 4
10 (HEK/DOR) b
inhibition of DPDPE (10 μM) activity by 10
(HEK/DOR)
7.4 ± 0.3
aMean ± SE of 5−6 independent experiments performed in triplicate.
b10 (10−12−10−4 M) did not alter forskolin-induced cAMP formation.
Figure 4. Effect of 9 on the number of writhes produced by AcOH.
Vehicle or 9 was administered ip 5 min before ip injection of AcOH.
DOR antagonist NTD, KOR antagonist norBNI, and not selective
antagonist NLX were ip administered at the indicated doses 15, 30, or
10 min prior to 9, respectively. Data are the mean ± SEM of 6−8
mice/group: (∗) p < 0.05 vs mice treated with vehicle alone; (∗∗∗) P
< 0.001 vs mice treated with vehicle alone or with naloxone + 9
(Dunnett multiple comparison test after ANOVA).
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responses; in fact, administered at analgesic doses, 9 did not
cause (within 6 h) any significant alteration of spontaneous
locomotor activity or circling behavior, Straub tail, or grooming
(data not shown).
■ CONCLUSIONS
The CTP 1 and correlated peptides,1−8,15−17 including 9 and
10, constitute the new family of the tryptophan-containing
noncationizable opioid peptides (in short, TryCoNCOPs). In
contrast to most opioids, their atypical bioactivity resides in the
minimal pharmacophoric motif Trp&Phe, with indole NH
fundamental to ligand−receptor interaction. As a bunch of
picklocks, the cyclopeptides permit easy access to all ORs. The
significant preference of 9, 10, and 1 for MOR, DOR, and
KOR, respectively, seems to be correlated to specific γ- or β-
turn secondary structures. The MOR-selective ligand 9 revealed
full agonist activity in vitro, while 10 displayed significant
preference for DOR over MOR, acting as a strong DOR
antagonist and a weak agonist at MOR. Interestingly, 9 revealed
a strong, MOR-dependent antinociceptive effect in vivo upon
systemic administration, consistent with the cyclic nature.31,32 It
is well acknowledged that peripheral and central MOR may
contribute to modulate visceral pain.33−35 Thus, both sites may
contribute to analgesia elicited by 9. We plan to better address
this aspect in future investigations.
■ EXPERIMENTAL SECTION
General Methods. Chemicals, biological reagents, disposables,
cells, and animals were purchased from commercial sources. The MW-
assisted synthesis was performed at 40 W, using a MicroSYNTH
microwave lab station, monitoring the internal temperature with a
built-in ATC-FO advanced fiber optic automatic temperature control.
Purities were determined to be >95% by RP HPLC and elemental
analysis. Analytical RP HPLC was performed on an Agilent 1100
apparatus, using a C18 column Phenomenex Gemini 3 μm C18 110 Å
100 3 3.0 mm, mobile phase from 9:1 H2O/CH3CN to 2:8 H2O/
CH3CN (plus 0.1% HCOOH for the linear peptides) in 20 min at a
flow rate of 1.0 mL min−1. Direct-phase HPLC analysis was done on a
Kromasil 60-5 Diol column, mobile phase hexane/2-propanol 60:40, at
a flow rate of 0.6 mL min−1. Semipreparative RP HPLC was performed
on a C18 RP column ZORBAX Eclipse XDBC18 PrepHT cartridge
21.2 3 150 mm 7 μm, mobile phase from 8:2 H2O−CH3CN to 100%
CH3CN, in 10 min, flow rate 12 mL min
−1. ESI analysis was
performed using a MS single quadrupole HP 1100MSD detector.
Elemental analyses were performed using a Thermo Flash 2000
CHNS/O analyzer. 1H NMR spectra were recorded using a Varian
Gemini apparatus at 400 MHz in 5 mm tubes in 8:2 DMSO-d6/H2O,
water suppression by presaturation. 13C NMR spectra were recorded
at 100 MHz. Chemical shifts are reported as δ values relative to
residual DMSO δ H (2.50 ppm). More details are in the Supporting
Information.
CTP Synthesis.16,17 The linear peptides were assembled on a Phe-
preloaded Wang resin (0.5 g, Phe loading 0.4−0.8 mmol/g). Fmoc
deprotection was performed with 20% piperidine in DMF (5 mL) for
2 min under MW irradiation. Fmoc-protected amino acids (0.6 mmol)
in DMF (5 mL) were coupled using TBTU/HOBt/DIPEA (0.6/0.6/
1.2 mmol) while bubbling N2 for 10 min under MW irradiation.
Peptide cleavage was done with TFA/TIPS/water/PhOH (7:1:1:1 v/
v, 15 mL), for 2 h at rt. The crude peptides which precipitated in ice-
cold Et2O (69−84% pure by RP HPLC) were utilized for cyclization
without further purifications. Peptides (0.1 mmol) in DMF (5 mL)
were added over 12 h using a temporized syringe to HATU/DIPEA
(0.4/1.0 mmol) in DMF (20 mL). After an additional 12 h of stirring,
the crude CTPs were isolated by semipreparative RP HPLC (>95%
pure by analytical RP HPLC and elemental analysis). For full
experimental details and analytical characterizations, see the
Supporting Information.
Displacement binding assays were performed in triplicate in HEK-
293 cells stably expressing the hORs, using [3H]DAMGO, [3H]-
diprenorphine, and [3H]U69,593 (Figure S3), to label MOR, DOR, or
KOR, as radioligands.8,15−17 In brief, compounds were incubated at 25
°C for 90 min in 100 mM Tris-HCl buffer and 0.3% BSA on cell
membranes in the concentration range 10−12−10−4 M; nonspecific
binding was determined in the presence of the cold ligands. Cells lysed
with 1 N NaOH were left in scintillation fluid for 8 h before counting.
The radioactivity trapped on filters presoaked with 0.3% polyethyle-
nimine was determined by liquid scintillation. Ki values were calculated
using the Cheng−Prusoff equation from the IC50. Full details are given
in the Supporting Information.
cAMP Test of 9 and 10. The agonist activity was determined in
triplicate by measuring the inhibition of forskolin-stimulated cAMP
accumulation in whole HEK/MOR and HEK/DOR cells.12 Cells were
incubated in serum-free medium containing 0.5 mM 3-isobutyl-1-
methylxanthine and exposed for 15 min to 10 μM forskolin without
and with 9 or 10 (0.001 nM to 100 μM) at 37 °C. cAMP
concentration was determined using a cAMP EIA kit. To evaluate 10
antagonist activity, HEK/DOR cells were incubated in serum-free
medium containing 0.5 mM 3-isobutyl-1-methylxanthine and exposed
for 15 min to 10 μM forskolin without and with 10 μM DPDPE and
10 (0.001 nM-100 μM) at 37 °C. See also the Supporting Information.
Visceral Pain Test (approved Prot. no. 29-IX/9, July 25, 2012). In
summary, antinociception was evaluated in treated or control mice by
counting stretching or writhing responses during 10 min after ip
injection of 0.6% w/v AcOH in water (0.1 mL/10 g).12,17 CTP 9,
opioid antagonists, or vehicle was administered before AcOH. Data are
expressed as mean ± SEM. Statistical significance was estimated by a
mixed two-factor analysis of variance (ANOVA) or by one-way
ANOVA and Dunnett post hoc test. p ≤ 0.05 was accepted as
significant. See also the Supporting Information.
Conformational Analysis.15,22,24 2D ROESY experiments were
performed in DMSO-d6/H2O (8:2). Cross-peak intensities were
classified as very strong, strong, medium, and weak and were
associated with distances of 2.3, 2.7, 3.3, and 5.0 Å, respectively.15,24
These distances were utilized as constraints in the MD simulations.27
The absence of Hα(i)−Hα(i+1) cross-peaks reasonably excluded cis
peptide bonds, so the ω bonds were set at 180°. The restrained MD
was conducted using the AMBER force field in a 30 Å × 30 Å × 30 Å
box of standard TIP3P models of equilibrated water.27 50 random
structures were subjected to a 50 ps restrained MD with a 50% scaled
force field at 1200 K, followed by 50 ps with full restraints, after which
the system was cooled in 20 ps to 50 K. The resulting structures were
minimized, and backbones were clustered by the rmsd analysis.27
Unrestrained MD simulations27 were conducted for 10 ns at 298 K
using periodic boundary conditions (Supporting Information).
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■ ABBREVIATIONS USED
MOR, DOR, KOR, μ-, δ-, κ-opioid receptor; CTP, cyclo-
tetrapeptide; CPP, cyclopentapeptide; MW, microwave; β-Ala,
γ-aminopropanoic acid; DIPEA, diisopropylethylamine; HOBt,
hydroxybenzotriazole; HBTU, O-benzotriazole-N,N,N′,N′-tet-
ramethyluronium hexafluorophosphate; HATU, 1-[bis-
(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]-
pyridinium 3-oxide hexafluorophosphate; RP, reversed phase;
SEM, standard error of the mean; Emax, maximal obtainable
effect; norBNI, norbinaltorphimine; NLX, naloxone; NTD,
naltrindole
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